Fly News Breaks for February 16, 2017
Feb 16, 2017 | 10:54 EDT
Griffen Securities analyst Zack Ajzenman raised his price target for Syneron Medical to $14 saying the Q4 results show the company's Emerging Products group continues to "exhibit traction." The stock remains "significantly discounted," Ajzenman tells investors in a post-earnings research note. He reiterates a Buy rating on Syneron.
News For ELOS From the Last 2 Days
There are no results for your query ELOS